
Slump in EBITDA reflects the challenging business environment.
Slump in EBITDA reflects the challenging business environment.
Should the deal fall through, Cresco said it has alternative strategies for growth.
The company is collaborating with Harvard Medical School and Massachusetts General Hospital for the trial.
The state's motion seeking summary judgment was filed last Friday.
The firm's first quarter ended with a net loss of $28 million.
A court date has been set for June 2, 2023.
The results position the company for future growth in the consumer health and wellness market.
Higher production costs is forcing the company to go lean.
The leadership change follows a period of financial reorganization for the company.
The DEA indicated it could revisit the matter if the Ninth Circuit Court remanded the case.
Unpack the industry with the daily cannabis newsletter for business leaders.
Unpack the industry with the daily cannabis newsletter for business leaders.